Endoscopy Unit, Monash Medical Centre, Clayton, Victoria, Australia.
Gastrointest Endosc. 2010 Jul;72(1):150-4. doi: 10.1016/j.gie.2010.01.065. Epub 2010 May 20.
Chronic radiation proctitis (CRP) manifests as rectal bleeding 12 to 24 months after pelvic radiotherapy. No criterion standard of treatment has been established, although argon plasma coagulation (APC) has increasingly become the treatment of choice. Previous studies have applied APC over multiple sessions, necessitating increased numbers of treatments.
To assess the safety and efficacy of large-volume APC application in the treatment of CRP with the intention of a single-session treatment protocol.
Prospective study.
Tertiary referral hospital.
Over an 8-year period, consecutive patients with CRP with rectal bleeding were prospectively enrolled.
Large-volume APC application to affected rectal mucosa.
Number of treatments, bleeding scores, complications.
Fifty patients (mean age 72.1 years; range 51-87 years) were treated; 45 were men (prostate cancer). The mean period between radiotherapy and initial APC treatment was 23 months (range 4-140 months). Seventeen (34%) patients had grade A endoscopic severity, 23 (46%) grade B, and 10 (20%) grade C. Other therapies failed in 16 (32%) patients. The mean number of treatments was 1.36 (range 1-3) with a mean follow-up of 20.6 months (range 6-48 months). Sixty-eight percent of patients were successfully treated after 1 session and 96% after 2 sessions. Bleeding scores improved in all patients (P < .001). Seventeen (34%) patients experienced short-term, self-limiting complications; 1 (2%) patient experienced a long-term complication.
Nonrandomized study.
Large-volume APC treatment was successful in the treatment of CRP, including those in whom other therapies had previously failed, and resulted in a decreased number of treatments compared with other published studies. The benefits were offset by an increased incidence of short-term complications but no increase in long-term complications.
慢性放射性直肠炎(CRP)在盆腔放疗后 12 至 24 个月出现直肠出血。虽然氩等离子凝固(APC)已越来越成为治疗选择,但尚未确立治疗的标准。以前的研究已经应用了多次 APC,因此需要增加治疗次数。
评估大容量 APC 应用于 CRP 治疗的安全性和有效性,以期制定单次治疗方案。
前瞻性研究。
三级转诊医院。
在 8 年期间,前瞻性招募了有直肠出血的 CRP 连续患者。
大容量 APC 应用于受影响的直肠黏膜。
治疗次数,出血评分,并发症。
共治疗了 50 例患者(平均年龄 72.1 岁;范围 51-87 岁);45 例为男性(前列腺癌)。放疗与首次 APC 治疗之间的平均时间为 23 个月(范围 4-140 个月)。17 例(34%)患者内镜严重程度为 A 级,23 例(46%)为 B 级,10 例(20%)为 C 级。16 例(32%)患者其他治疗失败。治疗次数的平均次数为 1.36 次(范围 1-3 次),平均随访时间为 20.6 个月(范围 6-48 个月)。68%的患者经 1 次治疗后成功,96%的患者经 2 次治疗后成功。所有患者的出血评分均改善(P <.001)。17 例(34%)患者出现短期、自限性并发症;1 例(2%)患者出现长期并发症。
非随机研究。
大容量 APC 治疗成功治疗了 CRP,包括那些先前其他治疗失败的患者,并且与其他已发表的研究相比,治疗次数减少。短期并发症的发生率增加,但长期并发症没有增加,这使得好处得到了弥补。